LIDOCAINE HYDROCHLORIDE INJECTION USP 20 MG — DIN 02422026
LIDOCAINE HYDROCHLORIDE : 20 MG · HIKMA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is LIDOCAINE HYDROCHLORIDE INJECTION USP?
LIDOCAINE HYDROCHLORIDE INJECTION USP 20 MG contains LIDOCAINE HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02422026, held by HIKMA CANADA LIMITED, supplied as SOLUTION for BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 17-Apr-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIDOCAINE HYDROCHLORIDE INJECTION USP used for?
Production of local or regional anesthesia by infiltration, peripheral nerve block (e.g., brachial plexus), and central neural techniques (e.g., epidural and caudal blocks).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lidocaine cost around the world?
Lidocaine is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 25 | 121 | USD███.██ |
| United Kingdom | hospital | 22 | 22 | GBP███.██ |
| United Arab Emirates | public | 11 | 16 | AED███.██ |
| Bahrain | retail (max) | 11 | 14 | BHD███.██ |
| South Africa | single exit price | 7 | 12 | ZAR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Saudi Arabia | public | 6 | 9 | SAR███.██ |
| Morocco | PPV (public price) | 8 | 8 | MAD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Australia | ex-manufacturer | 3 | 3 | AUD███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
225 pack listings across 113 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Lidocaine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Lidocaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
28 holders have a Canadian DIN containing Lidocaine, across 72 DINs, of which 26 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASPEN PHARMACARE CANADA INC. | 9 | 8 | XYLOCAINE 0.5%, XYLOCAINE 1%, XYLOCAINE 2%, XYLOCAINE JELLY 2%, XYLOCAINE SPRAY, +1 more | Sourceable in Canada |
| HIKMA CANADA LIMITED | 4 | 4 | LIDOCAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| AURO PHARMA INC | 4 | 2 | LIDOCAINE INJECTION BP | Sourceable in Canada |
| EUGIA PHARMA INC. | 4 | 2 | LIDOCAINE INJECTION BP | Sourceable in Canada |
| PFIZER CANADA ULC | 4 | 2 | LIDOCAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| FORMATIVE PHARMA INC. | 2 | 2 | LIDOCAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| LABORATOIRE AGUETTANT | 2 | 2 | LIDOCAINE HYDROCHLORIDE INJECTION | Sourceable in Canada |
| ODAN LABORATORIES LTD | 2 | 2 | LIDODAN ENDOTRACHEAL NON-AEROSOL SPRAY, LIDODAN VISCOUS 2% | Sourceable in Canada |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 | 1 | 1 | JELIDO | Sourceable in Canada |
| PHARMAZEUTISCHE FABRIK MONTAVIT GES M.B.H. | 1 | 1 | CATHEJELL | Sourceable in Canada |
| ALLEGIANCE HEALTHCARE CORPORATION | 7 | 0 | AMNIOCENTESIS TRAY 1%, ARTHROGRAM TRAY 1%, BASIC BIOPSY TRAY 1%, LUMBAR PUNCTURE TRAY 1%, LUMBAR PUNCTURE TRAY 1% PEDIATRIC/INFANT, +2 more | No marketed DIN |
| ASTRAZENECA CANADA INC | 7 | 0 | XYLOCAINE 0.5%, XYLOCAINE 1.5%, XYLOCAINE 2%, XYLOCAINE 2% EPIDURAL, XYLOCAINE 5% SPINAL, +2 more | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | BLOCK/INFILTRATION |
| Pack configuration (monograph) | 5 mL and 10 mL single-use plastic ampoules; 5 mL glass ampoules (1% only); 20 mL and 50 mL multi-dose glass vials with preservative. |
| Storage | Store at 15-30°C. Protect from light. (Note: Standard USP storage typically implied; specific text refers to stability section). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lidocaine |
|---|---|
| ATC code | N01BB02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02422026 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2422026 |
| Brand name | LIDOCAINE HYDROCHLORIDE INJECTION USP |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 20 MG |
| Market authorization holder | HIKMA CANADA LIMITED |
| Health Canada schedule | Ethical |
| ATC code | N01BB02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01BB |
| Current status | MARKETED |
| Status date | 17-Apr-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administer lowest effective dose. Adults: varies by procedure (e.g., 1% or 2%). Children: up to 5 mg/kg (7 mg/kg with epinephrine). Slow injection with frequent aspiration is recommended.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to amide-type local anesthetics or parabens. Preservative-containing solutions are contraindicated for epidural, spinal, intra-ocular, or retro-ocular administration.
Warnings and precautions
Risk of systemic toxicity (CNS and Cardiovascular). Not for intra-articular infusion (irreversible chondrolysis risk). Use caution in patients with epilepsy, bradycardia, or severe shock.
Is Lidocaine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for LIDOCAINE HYDROCHLORIDE INJECTION USP
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
26 of 72 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CATHEJELL | 20 MG | GEL | PHARMAZEUTISCHE FABRIK MONTAVIT GES M.B.H. | MARKETED | 02370840 |
| JELIDO | Strength | Gel | PENDOPHARM DIVISION OF PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 | MARKETED | 02469146 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 20 MG | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | 02500655 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 10 MG | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | 02500647 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02421984 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 00884154 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02422018 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 01901982 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02421992 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | FORMATIVE PHARMA INC. | MARKETED | 02534827 |
2 · Same class — other molecules in ATC N01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | AMNIOCENTESIS TRAY 1% · ANTECUBITAL CENT VENOUS CATHETERIZATION KIT · ARTHROGRAM TRAY 1% · ATELOCOLLAGEN IMPLANT · +39 more | 72 | 26 | Yes |
| Lidocaine, Combinations | 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP · 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION · ARROW CENTRAL VENOUS CATHETERIZATION KIT · ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT · +55 more | 72 | 16 | Yes |
| Articaine, Combinations | 4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) · 4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) · ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION · ORABLOC 1:100,000 · +10 more | 18 | 12 | Yes |
| Bupivacaine | BUPIVACAINE HEAVY INJECTION BP · BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% · +12 more | 42 | 10 | Yes |
| Mepivacaine | 3% POLOCAINE DENTAL · CARBOCAINE 1% · CARBOCAINE 2% · CARBOCAINE 3% · +7 more | 15 | 7 | Yes |
| Ropivacaine | NAROPIN · NAROPIN INJ 7.5MG/ML · ROPIVACAINE HYDROCHLORIDE INJECTION · ROPIVACAINE HYDROCHLORIDE INJECTION USP · +2 more | 13 | 6 | Yes |
| Bupivacaine, Combinations | BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION · MARCAINE · MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ · MARCAINE E · +5 more | 12 | 5 | Yes |
| Prilocaine, Combinations | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 · DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 · EMLA CREAM · EMLA PATCH · +1 more | 5 | 4 | Yes |
| Combinations | CETACAINE LIQUID · ORAQIX | 2 | 2 | Yes |
| Prilocaine | 4% CITANEST PLAIN DENTAL · DENTSPLY 4% PRILOCAINE HYDROCHLORIDE DENTAL INJECTION | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01BA | Benzocaine · Chloroprocaine · Combinations,Of Anesthetics · Procaine · Tetracaine | 13 | 1 |
| N01BX | Phenol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LIDOCAINE HYDROCHLORIDE INJECTION USP called?
The same molecule, Lidocaine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Lignox | Latin | Saudi Arabia |
| VERSATIS | Latin | Bahrain, Czechia |
| Depo-medrol with Lidocaine | Latin | South Africa |
| Lidocaine Eva | Latin | Saudi Arabia |
| PLIAGLIS | Latin | Bahrain |
| Pliaglis® | Latin | United Arab Emirates |
| PRILA | Latin | Bahrain |
| Xylocaine | Latin | Bahrain, South Africa |
| xylocream® | Latin | United Arab Emirates |
| AVOCAINE | Latin | Bahrain |
| BelOcain vet. | Latin | Iceland |
| EMLA | Latin | Bahrain |
| Ennla | Latin | Saudi Arabia |
| Haemoproct | Latin | United Arab Emirates |
| Haemoproct Cream | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.